Gray Market Peptide Sales Surge 700% as Americans Use Bitcoin for Unapproved Drugs

Woofun AI reports that a new payment use case has emerged in the United States, where ordinary consumers are utilizing Bitcoin to acquire experimental weight-loss drugs from overseas vendors, a trend highlighted by Bloomberg. This phenomenon is driven by the high cost of legitimate pharmaceuticals and the regulatory gray areas surrounding unapproved compounds, with annual transaction volumes projected to exceed $100 million. The core driver is not speculative investment but rather a pragmatic attempt to access cost-effective health solutions that are otherwise unavailable through traditional channels.

The financial motivation behind these transactions is starkly illustrated by the experience of Zach, a 49-year-old market director from the Pacific Northwest. Previously skeptical of digital assets, he spent several days navigating the complexities of opening an account and transferring funds to purchase 20 bottles of semaglutide, a drug developed by Eli Lilly. The total cost for this year’s supply was $240, a fraction of the $300 per month, or $3,600 per year, that he would have paid to U.S. resellers. To execute this transfer, Zach opened a Coinbase account, marking his first interaction with cryptocurrency, solely because the Chinese seller required payment in Bitcoin. The significant price disparity compelled him to accept the perceived risks, leading him to follow a webpage guide to buy and send the coins, receiving his package within a week.

The drug in question, semaglutide, belongs to the class of GIP, GLP-1, and glucagon triple receptor agonists, which targets more receptors than existing market options like tirzepatide. Eli Lilly released phase III clinical data in March this year, demonstrating that at the highest dose, weight loss could reach 28% over 80 weeks. Despite these promising results, the drug has not yet been approved by the FDA, rendering it unavailable through legitimate U.S. channels. Zach’s search for the compound led him to a Chinese seller who offered the unapproved substance at a steep discount, contingent upon the use of Bitcoin for payment. This requirement excluded traditional banking methods, forcing buyers into the crypto ecosystem.

Peptides, defined as short chains of amino acids that regulate various physiological processes, have gained public attention alongside the weight-loss drug trend. While FDA-approved injectable drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) are peptide-based, a parallel market exists for untested products labeled as "research chemicals." These substances, often shipped directly from overseas laboratories, carry clear warnings that they are not FDA-approved and not intended for human or animal use. They operate outside the scope of prescriptions and insurance coverage, creating a niche for consumers willing to bypass regulatory safeguards in pursuit of weight loss.

Traditional payment systems, including banks and credit card networks, frequently refuse to serve sellers of these unapproved peptides due to unproven health claims and high legal risks. Consequently, many sellers have turned to Bitcoin as their primary payment method.

However, a hierarchy exists within cryptocurrency payments: while Bitcoin remains the mainstream choice for small-scale individual buyers like Zach, stablecoins have surpassed Bitcoin as the preferred method for sellers with average transaction amounts exceeding $1,000. This distinction highlights the evolving nature of crypto adoption in gray markets, where transaction size dictates the choice of digital asset.

Woofun AI data shows that gray-market peptide sellers received $32 million in cryptocurrency payments in the first quarter of 2026, according to Chainalysis. This represents a 700% increase year-on-year, rising from $12 million in the previous quarter, a 159% sequential jump. At this pace, the annual volume is set to exceed $100 million. TRM Labs, using a different methodology that combines on-chain analysis with investigations into drug precursor manufacturers, estimated $41.4 million in cryptocurrency inflows into this sector in 2025, a 20% increase year-on-year. Ari Redbord, TRM Labs’ global policy director, noted the rapid expansion, stating, "This market is huge and expanding. I’m not sure of any other pharmaceutical market growing as fast as peptides."

Despite the rapid growth, the overall size of the peptide black market is estimated by industry investors to range from $1 billion to $3 billion, meaning cryptocurrency payments still constitute a small fraction of total transactions. The demographic overlap between crypto users and biohackers is evident in events like DeSciNYC, a monthly gathering in Manhattan for science enthusiasts. At a recent session titled "Peptides 101," Julius Ritter, founder of the California Peptide Club and operator of a longevity-themed food delivery company in San Francisco, discussed peptide chemistry and risks. The event, held in a bar decorated with cryptocurrency memorabilia, attracted over a hundred attendees, illustrating the cultural convergence of these communities.

Regulatory shifts may soon disrupt this market. The FDA is convening advisory committees to discuss the feasibility of allowing legal production of certain popular peptides within the U.S. Robert Kennedy Jr., Secretary of Health and Human Services, supports this approach, arguing that legalization "will help shift demand away from the black market." Lee Rosebush, president of the American Peptide Society, described the current situation as a "wild west," believing that stricter rules will eliminate manufacturers producing only for research purposes. If legalization proceeds, the reliance on Bitcoin for these transactions may diminish, as traditional payment systems could re-enter the market.

Zach’s engagement with this gray market is temporary; he plans to quit once he reaches his target weight. His journey reflects a broader trend where consumers prioritize cost savings over regulatory compliance, driving a surge in Bitcoin usage for niche pharmaceutical purchases. As the FDA considers legalization, the future of this payment use case remains uncertain, potentially facing obsolescence if traditional payment systems regain access to the peptide market.